Invivyd Inc. reports Q3 net product revenue of $13.1 million
Invivyd Inc. reported net product revenue of $13.1 million for PEMGARDA (pemivibart) in the third quarter of 2025, reflecting a 41% year-over-year increase and 11% growth compared to the previous quarter. The company ended the third quarter of 2025 with $85.0 million in cash and cash equivalents, and over $100 million by the end of October 2025. Invivyd completed a public offering in August 2025, raising approximately $57.5 million in gross proceeds, and generated an additional $29.8 million through an at-the-market offering facility in October 2025. Business developments during the period included the U.S. IND clearance and FDA alignment for the VYD2311 pivotal clinical program, expanded commercial activity for PEMGARDA among healthcare providers treating immunocompromised patients, new leadership appointments, and the formation of the SPEAR Study Group to assess monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-268057), on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.